Syros Pharmaceuticals, Inc.
SYRSDelisted Mar 10, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001556263
Syros Pharmaceuticals, Inc. was delisted on Mar 10, 2025; its insiders filed their last Form 4 on Dec 4, 2024; 44 institutions reported holding it in 13F filings for Q4 2024, worth $1.20M in total; no superinvestor held it.
Q3 2024 vs. Q2 2024
How the institutions holding Syros Pharmaceuticals, Inc. changed between Q2 2024 and Q3 2024.
All holders in Q3 2024All holders in Q2 2024
| Measure | Q2 2024 | Of which not filed for Q3 2024 | Q3 2024 | Change |
|---|---|---|---|---|
| Holders | 70 | 1 | 65 | −4 |
| Shares | 20.4M | 259.2K | 19.0M | −1.17M (−5.8%) |
| Value | $105.2M | $1.34M | $40.8M | −$63.1M (−60.8%) |
1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (13)
Institutions that held Syros Pharmaceuticals, Inc. at the end of Q3 2024 but not at the end of Q2 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Siren, L.L.C. | 2,587,372 | $5.56M | 0.28% |
| BlackRock, Inc. | 261,579 | $562.4K | 0.00% |
| Pale Fire Capital SE | 49,211 | $105.8K | 0.02% |
| ADAR1 Capital Management, LLC | 45,000 | $96.8K | 0.02% |
| XTX Topco Ltd | 28,834 | $62.0K | 0.00% |
| Virtu Financial LLC | 19,629 | $42.0K | 0.00% |
| Gsa Capital Partners LLP | 15,905 | $34.0K | 0.00% |
| Marex Group plc | 12,700 | $27.3K | 0.00% |
| Centerpoint Advisors, LLC | 10,659 | $23.0K | 0.01% |
| Wiser Wealth Management, Inc | 10,000 | $21.5K | 0.01% |
| Aster Capital Management (DIFC) Ltd | 9,970 | $21.4K | 0.00% |
| Citigroup Inc | 687 | $1.48K | 0.00% |
| FMR LLC | 2 | $4 | 0.00% |
Sold out (17)
Institutions that held Syros Pharmaceuticals, Inc. at the end of Q2 2024 and filed for Q3 2024 without it.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| Artal Group S.A. | 2,505,013 | $12.9M |
| Kennedy Capital Management, Inc. | 427,536 | $2.21M |
| Goldman Sachs Group Inc | 262,373 | $1.35M |
| DAFNA Capital Management LLC | 135,850 | $701.0K |
| LPL Financial LLC | 76,625 | $395.4K |
| LGT Capital Partners Ltd. | 55,000 | $283.8K |
| Jane Street Group, LLC | 39,181 | $202.2K |
| Superstring Capital Management LP | 37,789 | $195.0K |
| Susquehanna International Group, LLP | 30,005 | $154.8K |
| Citadel Advisors LLC | 26,622 | $137.4K |
| Assenagon Asset Management S.A. | 15,873 | $81.9K |
| Simplex Trading, LLC | 14,091 | $72.0K |
| Edmond de Rothschild Holding S.A. | 4,382 | $22.6K |
| Redwood Wealth Management Group, LLC | 1,157 | $5.97K |
| National Bank of Canada | 859 | $4.23K |
| Rhumbline Advisers | 659 | $3.40K |
| Aviso Financial Inc. | 21 | $108 |
Not filed for Q3 2024 yet (1)
Institutions that held Syros Pharmaceuticals, Inc. at the end of Q2 2024 and haven't filed a 13F for Q3 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| BlackRock Inc. | 259,189 | $1.34M |